NSC 697726

RH1 exhibits antitumor activity in a dose-dependent manner against NQ16 tumors growing in athymic mice. RH1 treatment (0.4 mg/kg and 0.2 mg/kg) of mice bearing NQ16 tumors results in a significant reduction in tumor volume between treated groups and controls as early as 5 days after the treatment period ended. Low-dose RH1 (0.1 mg/kg) also results in a significant reduction in tumor volume between treated mice and controls^[2].